Spots Global Cancer Trial Database for biosimilar
Every month we try and update this database with for biosimilar cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Comparing Study Between ALT02(Trastuzumab Biosimilar) and Herceptin® in Healthy Subjects | NCT03242239 | Healthy | ALT02 EU-licensed Her... US-licensed Her... | 18 Years - 55 Years | Alteogen, Inc. | |
| Safety Study of Remsima® (Infliximab) in Rheumatoid Arthritis Patients in Jordan | NCT03348046 | Rheumatoid Arth... | Biosimilar Infl... | 18 Years - | Hikma Pharmaceuticals LLC | |
| Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of MW032 and Xgeva® in Healthy Adults | NCT04798326 | Bone Tumor | MW032 Xgeva® | 18 Years - 65 Years | Mabwell (Shanghai) Bioscience Co., Ltd. | |
| HER2-directed Biosimilar in Breast Cancer: Real World ePRO | NCT05234021 | HER2-positive B... Biosimilar Patient Reporte... | 18 Years - | OnkoZentrum Zürich AG | ||
| Safety and Effectiveness Study of Remsima® in the Treatment of Inflammatory Bowel Diseases Among Saudi Arabia Patients | NCT03452501 | Inflammatory Bo... Crohn Disease Fistulizing Cro... Ulcerative Coli... | Infliximab | 18 Years - | Hikma Pharmaceuticals LLC | |
| A Long-term Follow-up Study for Cardiac Safety in the Patients With HER2 (+) Breast Cancer Who Have Completed the SB3-G31-BC | NCT02771795 | Breast Neoplasm... | Herceptin (tras... SB3 (proposed t... | 18 Years - | Samsung Bioepis Co., Ltd. | |
| GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL) | NCT01419665 | Follicular Lymp... | GP2013 rituximab | 18 Years - | Sandoz | |
| A Comparing Study Between ALT02(Trastuzumab Biosimilar) and Herceptin® in Healthy Subjects | NCT03242239 | Healthy | ALT02 EU-licensed Her... US-licensed Her... | 18 Years - 55 Years | Alteogen, Inc. | |
| A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer | NCT04466917 | Metastatic Non-... Non-squamous NS... | ABP 215 Bevacizumab Paclitaxel Carboplatin | 18 Years - 80 Years | Amgen | |
| GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL) | NCT01419665 | Follicular Lymp... | GP2013 rituximab | 18 Years - | Sandoz | |
| Safety and Effectiveness Study of Remsima® in the Treatment of Inflammatory Bowel Diseases Among Saudi Arabia Patients | NCT03452501 | Inflammatory Bo... Crohn Disease Fistulizing Cro... Ulcerative Coli... | Infliximab | 18 Years - | Hikma Pharmaceuticals LLC | |
| Safety and Effectiveness Study of Remsima® in the Treatment of Inflammatory Bowel Diseases Among Saudi Arabia Patients | NCT03452501 | Inflammatory Bo... Crohn Disease Fistulizing Cro... Ulcerative Coli... | Infliximab | 18 Years - | Hikma Pharmaceuticals LLC | |
| A Study to Compare the Effect of SB3 and Herceptin® in Women With HER2 Positive Breast Cancer | NCT02149524 | HER2 Positive E... | Herceptin (tras... SB3 (proposed t... | 18 Years - 65 Years | Samsung Bioepis Co., Ltd. | |
| A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer | NCT04466917 | Metastatic Non-... Non-squamous NS... | ABP 215 Bevacizumab Paclitaxel Carboplatin | 18 Years - 80 Years | Amgen | |
| Comparative Clinical Trial of Efficacy and Safety of BCD-057 and Humira® in Patients With Moderate to Severe Plaque Psoriasis | NCT02762955 | Psoriasis | BCD-057 Humira® | 18 Years - 75 Years | Biocad | |
| A Long-term Follow-up Study for Cardiac Safety in the Patients With HER2 (+) Breast Cancer Who Have Completed the SB3-G31-BC | NCT02771795 | Breast Neoplasm... | Herceptin (tras... SB3 (proposed t... | 18 Years - | Samsung Bioepis Co., Ltd. | |
| A Study to Learn About the Study Medicine Called Infliximab (Genetical Recombination)[Infliximab Biosimilar 3] in People With Rheumatoid Arthritis, Ulcerative Colitis, Crohn's Disease, or Psoriasis | NCT05796245 | Arthritis, Rheu... Colitis, Ulcera... Crohn Disease Psoriasis | 15 Years - | Pfizer | ||
| Comparative Clinical Trial of Efficacy and Safety of BCD-057 and Humira® in Patients With Moderate to Severe Plaque Psoriasis | NCT02762955 | Psoriasis | BCD-057 Humira® | 18 Years - 75 Years | Biocad | |
| Study for Late Assessment of the Safety and Efficacy of Biosimilar Rituximab | NCT04928573 | Diffuse Large B... | - | Libbs Farmacêutica LTDA | ||
| A Comparing Study Between ALT02(Trastuzumab Biosimilar) and Herceptin® in Healthy Subjects | NCT03242239 | Healthy | ALT02 EU-licensed Her... US-licensed Her... | 18 Years - 55 Years | Alteogen, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
